Lantheus Reports Third Quarter 2026 Financial Results

Lantheus reported third-quarter 2026 worldwide revenue of $389.9 million and adjusted diluted EPS of $1.68, up from $1.27 a year earlier; GAAP diluted EPS fell to $0.33 from $0.41. The FDA approved TAUKLARIFY for tau PET imaging in adults with cognitive impairment being assessed for Alzheimer’s disease and granted final approval to BRAVNETSA for certain GEP-NETs. The company also noted its previously announced definitive merger agreement with Curium, an all-cash transaction valued at up to approximately $8.0 billion.

Analysis

The merger makes deal completion—not near-term earnings momentum—the main driver of LNTH’s equity. In an all-cash transaction, stronger operating results are more likely to support closing confidence than create uncapped upside for shareholders; the “up to” transaction value is not enough to infer the per-share consideration or current arbitrage spread. The key diligence items are the precise cash consideration, conditions to closing, termination rights or fees, financing certainty, and expected timetable.

The quarter is mixed rather than a clean fundamental re-rating signal: adjusted EPS improved year over year while GAAP EPS declined, and the supplied data lack revenue comparatives, guidance, and a reconciliation explaining that divergence. The two FDA approvals may improve the strategic asset base and Curium’s prospective economics, but product-level adoption, reimbursement, launch costs, and sales contribution are unverified. With the deal outstanding, those benefits primarily matter through execution and closing risk unless the agreement permits repricing or termination.

Near term, monitor the LNTH-to-cash-consideration spread and deal updates. Over 1–3 months, regulatory, shareholder, and other closing milestones can dominate earnings headlines; over 6–18 months, uptake of the newly approved products matters more to the combined business than to LNTH holders if the cash deal closes. A contrarian risk is treating upbeat adjusted EPS and approvals as standalone upside catalysts while overlooking that deal terms cap the payoff. Conversely, a wider spread may price in failure risk that the quarter alone cannot resolve.

Key Decisions for Investors

• Treat LNTH as an event-driven position, not a conventional earnings-growth long, until the merger terms and closing path are verified. Calculate the gross spread from the current share price to the exact cash consideration; do not use the stated transaction value as a per-share offer price.
• Consider a merger-arbitrage position only if the verified spread adequately compensates for time to close and break risk. Size against a downside case using LNTH’s standalone value, which is not established by the supplied data; avoid assuming the offer is guaranteed.
• Track the next deal milestones and any change to conditions, timetable, financing, or termination provisions. A material delay, adverse regulatory development, or buyer/target disclosure weakening closing certainty would falsify the low-risk-arbitrage case and likely widen the spread.
• For fundamental diligence, request revenue growth by product, forward guidance, the GAAP-to-adjusted EPS reconciliation, and launch/adoption evidence for both approved products. Without those data, there is no basis here for a standalone earnings-driven re-rating trade.